NL-OMON37516已完成不适用
Study of the pharmacokinetics of Infliximab (IFX) in moderate to severe Ulcerative Colitis - KINETIC druglevel Infliximab
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Age from 18 years, either male or female
- •-Moderate to severe Ulcerative Colitis (according to Mayo score (2 or 3) baseline Colonoscopy) naïve to biologic therapy.
- •-Baseline Colonoscopy
- •-Obtained written informed consent
排除标准
- •-History of anti-TNF treatment
- •-Contra-indication to infliximab: TBC, severe infections or congestive heart failure.
- •-Imminent need for surgery
- •-Immunomodulators started in the last 4 weeks
研究者
相似试验
进行中（未招募）
不适用
The degradation and elimination of InfliximabInflammatory bowel disease (Ulcerative Colitis, Crohn's disease)MedDRA version: 17.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 17.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-001332-29-ATniversitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie
尚未招募
4 期
Pro-RAPIDCrohn's Disease2023-507352-72-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)50
尚未招募
4 期
Prospective Analysis of Pharmacokinetic Infliximab data in Paediatric Inflammatory Bowel Disease patientsCrohn's diseaseNL-OMON51805Erasmus MC, Universitair Medisch Centrum Rotterdam49
进行中（未招募）
1 期
Prospective Analysis of Pharmacokinetic Infliximab data in Paediatric Inflammatory Bowel Disease patients (Pro-RAPID)Crohn's DiseaseCTIS2023-507352-72-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)50
已完成
不适用
Integrated pharmacokinetics of infliximab, adalimumab and golimumab in serum, tissue and faeces of patients with moderate to severe Ulcerative Colitis and Crohn's Colitisinflammatory bowel diseaseulcerative colitis/Crohn's colitis10017969NL-OMON47648Maag-, darm-, leverziekten60